Journey Medical Corporation announced that it received notice from its exclusive licensing partner in Japan, Maruho Co. Ltd. that Japan's Ministry of Health, Labor and Welfare approved Rapifort Wipes 2.5% for the treatment of primary axillary hyperhidrosis. This approval triggers a milestone payment of $10 million to Journey Medical, $7.5 million of which will be paid to Dermira Inc., pursuant to the terms of the Asset Purchase Agreement between Journey and Dermira, with net proceeds of $2.5 million to Journey.

Pursuant to the terms of the agreement with Maruho, the milestone payment is due from Maruho within 30 days. Journey Medical acquired global rights to QBREXZA from Dermira in 2021. QBREXZA is a topical product approved by the U.S. Food and Drug Administration for treatment of primary axillary hyperhidrosis in adult and pediatric populations and is self-administered by patients.

Additionally, QBREXZA is noted as a first-line therapy for primary axillary hyperhidrosis by the International Hyperhidrosis Society.